Close Menu

Group A streptococcus

Credo Diagnostics recently received the CE mark for the coronavirus test, which can provide results in 20 minutes.

Researchers identified Streptococcus pyogenes isolates from a lineage dubbed M1UK that are predicted to produce higher-than-usual levels of a scarlet fever-associated toxin.

The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.

Despite the diversity detected in Group A Streptococcus strains from more than 20 countries, investigators narrowed in on broadly shared sequences with relatively low variation.

The test detects Group A Strep in throat swab samples using the firm's rapid molecular diagnostics instrument called Revogene.

The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Researchers used genomic, transcriptomic, and virulence data on thousands of Streptococcus pyogenes strains to identify features influencing infections.

Abbott said that the next-generation molecular POC assays have also been CLIA waived for use on the Abbott ID NOW instrument, formerly called Alere i.

The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.

Pages

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.